Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 21, 2014; 20(19): 5583-5593
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5583
Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5583
Immune responses to Helicobacter pylori infection
Mati Moyat, Dominique Velin, Service of Gastroenterology and Hepatology, Department of Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland
Author contributions: Moyat M and Velin D wrote the paper.
Supported by the Swiss National Foundation grants 310030_141145, to Velin D
Correspondence to: Dominique Velin, PhD, Service of Gastroenterology and Hepatology, Department of Medicine, Lausanne University Hospital, BH18-521, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. dominique.velin@chuv.ch
Telephone: +41-21-3140685 Fax: +41-21-3149653
Received: September 27, 2013
Revised: December 14, 2013
Accepted: February 20, 2014
Published online: May 21, 2014
Processing time: 232 Days and 21.3 Hours
Revised: December 14, 2013
Accepted: February 20, 2014
Published online: May 21, 2014
Processing time: 232 Days and 21.3 Hours
Core Tip
Core tip:Helicobacter pylori (H. pylori) infection is one of the most common infections in human beings worldwide. H. pylori actively induce tolerogenic signals and can be considered as a commensal bacteria belonging to the stomach microbiota. However, H. pylori also promote a chronic inflammation in the gastric mucosa and the direct action of virulence factors confers pro-carcinogenic activities to H. pylori. Hence, H. pylori cannot be considered as symbiotic bacteria but rather as part of the pathobiont. The development of a H. pylori vaccine will bring health benefits for individuals infected with antibiotic resistant H. pylori strains and population of underdeveloped countries.